SCHEMBL2820980

SCHEMBL2820980

Cc1nc2cc(Cl)c(Cl)cc2c(O)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.37
PTPN1 P18031 1/20 0.37
MAPT P10636 3/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ACHE P22303 1/20 0.34
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
NQO2 P16083 1/20 0.33
PDE10A Q9Y233 1/20 0.33
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
STAT3 P40763 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821680 0.86 PTGS2 (0.36) HRH4PTPN1MAPTKMT2AKDM4E
SCHEMBL2126008 0.78 KDM4E (0.51) PTPN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL2819742 0.77 KDM1A (0.33) MAPTKDM4EALDH1A1PDE10AGAA
SCHEMBL1149078 0.76 CCNC (0.37) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL1148175 0.76 KMT2A (0.46) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL1149219 0.76 LDHA (0.40) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL1148254 0.75 SIRT1 (0.41) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL1148847 0.75 RAF1 (0.39) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL13107066 0.73 KDM4E (0.49) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL1149140 0.73 GRM8 (0.39) MAPTKMT2AKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C HRH4 8/4885PTPN1 458/4885MAPT 4564/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 HRH4 90/4885PTPN1 221/4885MAPT 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.